Get the Stockscreener App
4.90
2.51%
0.12
Lexeo Therapeutics Inc stock is traded at $4.90, with a volume of 518.91K.
It is up +2.51% in the last 24 hours and up +25.96% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
See More
Previous Close:
$4.78
Open:
$4.83
24h Volume:
518.91K
Relative Volume:
0.96
Market Cap:
$162.67M
Revenue:
-
Net Income/Loss:
$-86.60M
P/E Ratio:
-1.73
EPS:
-2.8324
Net Cash Flow:
$-67.37M
1W Performance:
+3.81%
1M Performance:
+25.96%
6M Performance:
+25.96%
1Y Performance:
-59.77%
1-Day Range:
$4.80
$5.115
1-Week Range:
$4.5601
$5.115
52-Week Range:
$1.45
$12.37
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
4.90 | 265.69M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Top Executives at Lexeo Therapeutics Make Significant Stock Sales! - TipRanks
Lexeo Therapeutics Executives Sell Shares at $4.67/Share on 2025-08-18. - AInvest
How institutional ownership impacts Lexeo Therapeutics Inc. stockJuly 2025 Spike Watch & Accurate Intraday Trade Tips - Newser
How to recover losses in Lexeo Therapeutics Inc. stockAnalyst Downgrade & Entry and Exit Point Strategies - Newser
Lexeo Therapeutics’ Friedreich Ataxia Gene Therapy Receives FDA Breakthrough Therapy Designation - MSN
Lexeo Therapeutics price target lowered to $15 from $20 at Chardan - MSN
How to interpret RSI for Lexeo Therapeutics Inc. stock2025 Breakouts & Breakdowns & Consistent Profit Alerts - Newser
Lexeo Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowJuly 2025 Summary & Verified Technical Signals - Newser
Why Lexeo Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Macro Moves & Weekly Top Performers Watchlists - kangso.co.kr
Chardan Cuts Price Target on Lexeo Therapeutics to $15 From $20, Keeps Buy Rating - MarketScreener
Lexeo Therapeutics Q2 Earnings Misses, Yet Market Reacts Positively — Here’s What Investors Should Know - AInvest
Custom watchlist performance reports with Lexeo Therapeutics Inc.2025 Market Trends & Weekly High Return Stock Forecasts - Newser
Will Lexeo Therapeutics Inc. stock split in the near future2025 Support & Resistance & Free Safe Capital Growth Stock Tips - Newser
Lexeo Therapeutics Posts Q2 2025 Earnings Loss, But Backtests Suggest Strong Post-Miss Recovery - AInvest
HC Wainwright Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $9.00 - Defense World
Quantitative breakdown of Lexeo Therapeutics Inc. recent moveWeekly Gains Summary & Detailed Earnings Play Strategies - Newser
Chardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price - Defense World
Can machine learning forecast Lexeo Therapeutics Inc. recovery2025 Big Picture & Community Trade Idea Sharing Platform - Newser
Lexeo Therapeutics Inc. Stock Approaches Key Moving AveragePortfolio Risk Report & Fast Entry Momentum Alerts - metal.it
Heatmap analysis for Lexeo Therapeutics Inc. and competitors2025 Stock Rankings & Free AI Powered Buy and Sell Recommendations - Newser
What data driven models say about Lexeo Therapeutics Inc.’s futureMarket Growth Summary & Free Fast Gain Swing Trade Alerts - Newser
Is Lexeo Therapeutics Inc. affected by consumer sentimentWeekly Stock Summary & Safe Capital Growth Trade Ideas - 선데이타임즈
Is now the right time to enter Lexeo Therapeutics Inc.Exit Point & Fast Momentum Stock Entry Tips - 선데이타임즈
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Clover Health Investments (CLOV) and Xilio Therapeutics (XLO) - The Globe and Mail
Measuring Lexeo Therapeutics Inc.’s beta against major indicesWeekly Stock Report & Risk Managed Investment Strategies - Newser
Lexeo Therapeutics Inc. stock momentum explained2025 Trading Volume Trends & Safe Entry Zone Tips - Newser
Is Lexeo Therapeutics Inc. stock poised for growthWeekly Trade Report & Free Safe Capital Growth Stock Tips - Newser
How to forecast Lexeo Therapeutics Inc. trends using time seriesMarket Volume Report & High Win Rate Trade Alerts - Newser
Price momentum metrics for Lexeo Therapeutics Inc. explained2025 Market Outlook & Momentum Based Trading Signals - Newser
Will Lexeo Therapeutics Inc. Recover After Recent DeclineReliable High Profit Alerts - beatles.ru
Chart Analysts Warn of Resistance Near Lexeo Therapeutics Inc. PriceEntry Point & Free Accurate Trade Setup Notifications - 선데이타임즈
Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Strategic Positioning in Cardiac Treatments - TipRanks
Lexeo Therapeutics stock price target lowered to $9 at H.C. Wainwright - Investing.com
Lexeo Therapeutics: HC Wainwright Maintains Buy Rating, Lowers PT to $9 from $15. - AInvest
How high can Lexeo Therapeutics Inc. stock price go in 2025Market Risk Analysis & Free Real-Time Market Sentiment Alerts - Newser
Lexeo Therapeutics Reports Q2 2025 Financial Results - TipRanks
Lexeo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Lexeo Reports Q2 Loss as Costs Jump 129% - sharewise.com
Lexeo Therapeutics Reports Q2 Loss as Administrative Costs Surge 129% - AInvest
Lexeo Therapeutics: Can a Deep Pipeline and Regulatory Momentum Offset Earnings Woes? - AInvest
Lexeo Therapeutics Appoints New Chief Financial Officer - TipRanks
Lexeo Therapeutics appoints Louis Tamayo as CFO - MarketScreener
Lexeo Therapeutics, Inc. SEC 10-Q Report - TradingView
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights - GlobeNewswire
Lexeo Therapeutics, Inc. Announces the Appointment of Louis Tamayo Principal Accounting Officer - MarketScreener
Lexeo Therapeutics, Inc. Announces CFO Changes - MarketScreener
How Lexeo Therapeutics Inc. stock performs during market volatilityBuy/Sell Zone Confirmation Technical Analysis - Newser
What makes Lexeo Therapeutics Inc. stock price move sharplyLow Float Short Squeeze Picks - thegnnews.com
Lexeo Therapeutics Inc. Matches Institutional Buying FilterBuy Low Sell High Stock Watch Strategy in Focus - beatles.ru
Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO) - MSN
Lexeo Therapeutics (LXEO) Projected to Post Quarterly Earnings on Monday - Defense World
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexeo Therapeutics Inc Stock (LXEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Robertson Jenny | Chief Legal Officer |
Aug 18 '25 |
Sale |
4.67 |
542 |
2,530 |
62,556 |
| Adler Eric | Chief Medical Officer |
Aug 18 '25 |
Sale |
4.67 |
608 |
2,838 |
67,073 |
| Townsend Richard Nolan | Chief Executive Officer |
Aug 18 '25 |
Sale |
4.67 |
2,735 |
12,767 |
220,058 |
| See Tai Sandi | Chief Development Officer |
Aug 18 '25 |
Sale |
4.67 |
382 |
1,783 |
58,860 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):